Navigation Links
Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays.
Date:1/14/2010

CHICAGO, Jan. 14 /PRNewswire/ -- Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays.  The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.  These increases in performance could aid researchers in basic and clinical science research, drug discovery, and clinical diagnostics development.

"We find the resolution at low concentrations to be an exciting benefit in our ovarian cancer and infertility research," said Professor Judith Luborsky, Ph.D., Associate Dean for Research, College of Health Sciences, Director, Laboratory for Ovarian Cancer Research and Director, Rush Proteomics & Biomarkers Core Research Facility at Rush University Medical Center.  "The technology was easily integrated into existing tests with minimal optimization and provided excellent improvements.  In fact, we have included Sword technology in several grants we are currently applying for."

"We are pleased with the positive reception our technology has received from the market. The key opinion leaders have found it particularly useful for highly sensitive ELISAs," said Dave Dingott, founder and CEO of Sword Diagnostics.  "The Raman plate reader allows current ELISA users to continue using their 96-well format, making conversion to our technology extremely simple and cost effective."

About Sword Diagnostics

Sword Diagnostic's mission is to improve existing immunoassays by providing additional sensitivity to currently available antibody-based test as well as allowing researchers to monitor new markers that are not readily detectable with current technology.  This may lead to earlier and more accurate diagnosis of diseases such as cancer, cardiovascular disorders, and Alzheimer's disease.  Better diagnosis results in simpler treatments with more positive outcomes for patients and less costs.

Sword markets its technology for biomarker measurement for pharmaceutical drug discovery and academic life science researchers and will partner to develop clinical diagnostics assays.  The technical solution is an immunoassay detection system that uses Raman spectroscopy and a proprietary chemistry.  The system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.  

www.sworddiagnostics.com

SOURCE Sword Diagnostics Inc.

RELATED LINKS
http://www.sworddiagnostics.com

'/>"/>

SOURCE Sword Diagnostics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology
2. Inverness Medical Innovations Offers to Acquire Standard Diagnostics
3. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
4. Fujirebio Diagnostics Named Life Sciences Company of the Year
5. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
6. Roche Diagnostics Opens State-of-the-Art Training Center in California
7. Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition
8. Reportlinker Adds Molecular Diagnostics - A World Market Review
9. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
10. Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective
11. VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):